• Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

SCIENTIFIC PUBLICATIONS

Our medical oncologists and laboratory investigators are at the forefront of investigations into the causes of cancer and the search for novel treatments.

We have published the results of our investigations, often in collaboration with some of the most prestigious international institutions, in renowned medical journals such as the New England Journal of Medicine, Clinical Cancer Research, and many others.

CONSULT OUR SCIENTIFIC PUBLICATIONS

01/03/2015

Chemotherapy after surgery for early stage non-small cell lung cancer

AUTHORS Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y

PUBLICATION Non-Small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev. 2015 Mar 2;3:CD011430.

READ ARTICLE

01/02/2015

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer

AUTHORS Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R.

PUBLICATION Lung Cancer 87 (2015) 169–175

READ ARTICLE

01/02/2015

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

AUTHORS de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R.

PUBLICATION Future Oncology 2015 11(3), 421–429

READ ARTICLE

01/02/2015

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

AUTHORS Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Gonzalez Cao M, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG.

PUBLICATION Nat Genet. 2015 Feb 9. 2015 Mar;47(3):250-6

READ ARTICLE

19/11/2014

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

AUTHORS Rafael Rosell, Niki Karachaliou, Juergen Wolf, Sai-Hong Ignatius Ou

PUBLICATION The Lancet Respiratory Medicine

READ ARTICLE